ES009
/ Elpiscience
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
October 03, 2025
A first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the LILRB2 inhibitor ES009 in patients with advanced solid tumors
(SITC 2025)
- P1 | "As a monotherapy, ES009 showed preliminary antitumor activity, supporting further clinical development.Trial Registration ClinicalTrials.gov ID: NCT06007482Ethics Approval This study obtained ethics approval from the Bellberry Human Research Ethics Committee, the number/ID of the approval was 2023-06-715. Participants gave informed consent before taking part."
Clinical • First-in-human • Metastases • P1 data • PK/PD data • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Submandibular Gland Cancer
June 23, 2025
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=12 | Completed | Sponsor: Elpiscience Biopharma Australia Pty. Ltd. | Recruiting ➔ Completed | N=20 ➔ 12 | Trial completion date: Aug 2025 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Feb 2025
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Solid Tumor
September 26, 2023
Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia
(Businesswire)
- "Elpiscience Biopharmaceuticals...announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia. The objective of the trial is to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity."
Trial status • Oncology • Solid Tumor
September 13, 2023
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Elpiscience Biopharma Australia Pty. Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Oncology • Solid Tumor
August 23, 2023
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Elpiscience Biopharma Australia Pty. Ltd.
Metastases • New P1 trial • Oncology • Solid Tumor
October 06, 2022
ES009, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation
(SITC 2022)
- "Conclusions In summary, the anti-LILRB2 mAb ES009 has demonstrated great potential in the reversion of immune suppression in the TME, leading to promotion of anti-tumor immunity. We are currently advancing the development of ES009 into a clinical candidate."
IO biomarker • Oncology • Ovarian Cancer • Solid Tumor • ANGPT1
November 20, 2022
Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting
(Businesswire)
- "Elpiscience Biopharmaceuticals...presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting....Abstract No.: 1062 - LILRB2 is predominantly expressed in myeloid lineage cells. Human LILRB2 broadly binds to multiple ligands and contributes to immune suppression in the tumor microenvironment (TME). Anti-LILRB2 mAb ES009 has demonstrated superior effects in converting immunosuppressive myeloid cells into pro-inflammation phenotypes in in vitro and ex vivo models."
Preclinical • Oncology
October 21, 2022
Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
(Businesswire)
- "Elpiscience Biopharmaceuticals...announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight studies on five innovative molecules including anti-SIRPα monoclonal antibody ES004, anti-LAG3 monoclonal antibody ES005, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and PD-L1/SIRPα bispecific macrophage engager ES019."
Preclinical • Oncology
1 to 8
Of
8
Go to page
1